Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
2024年10月31日 - 11:54PM
Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech developing
off-the-shelf, genetically unmodified T cell therapeutics to treat
infectious disease and cancers, shares details of its partnership
with Microsoft (Nasdaq: MSFT) for Startups.
Through this partnership Tevogen.AI aims to achieve
two key objectives. The first objective is to apply the principles
of machine learning to rapidly expand Tevogen’s
ExacTcell™ pre-clinical pipeline by performing key simulations
based on the successful trial results of TVGN 489. This capability
may allow Tevogen’s research team to analyze large datasets across
the genome, yielding faster and more accurate target
identification. The second objective uses Microsoft’s advanced AI
tools to develop proprietary algorithms that decode the
interactions between human leukocyte antigens (HLA) and T cells.
This capability may expand Tevogen’s understanding of immune
responses and identify new therapeutic opportunities, especially in
areas with limited existing data.
Mittul Mehta, Chief Information Officer and Head of
Tevogen.AI commented “Insights from the technical resources at
Microsoft, the world’s leading AI company, identified which tools
to utilize, thereby helping us build our data pipelines to
aggregate and normalize the appropriate datasets across the viral
spectrum. We aim to take these datasets and apply machine learning
models to speed up target selection. Subsequently, the refined data
will be used as part of our predictive AI technology to fulfil
areas that have insufficient data thereby allowing us to address
key interactions that haven’t been seen yet. Tevogen.AI will
continue working with Microsoft to advance the predictive modeling
by leveraging their expertise.”
“Through our partnership with Microsoft, we
anticipate an initial reduction in timelines of about 10%, with
further automation potentially allowing us to achieve reduction of
up to 30%. This preclinical modeling not only accelerates our
processes but also enhances accuracy, leading to direct and
tangible cost savings. These advancements support our goal of
bringing life-changing therapies to market in a faster and more
cost-efficient manner,” said Dr. Neal Flomenberg, Tevogen Bio’s
Chief Scientific Officer.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy
company harnessing CD8+ cytotoxic T lymphocytes, to develop
off-the-shelf, genetically unmodified T cell therapeutics to treat
infectious disease and cancers, aiming to address the significant
unmet needs of large patient populations. Tevogen leadership
believes that sustainability and commercial success in the current
era of healthcare rely on ensuring patient accessibility through
advanced science and innovative business models. Tevogen has
reported positive safety data from its proof-of-concept clinical
trial, and its key intellectual property assets are wholly owned by
the company, not subject to any third-party licensing agreements.
These assets include three granted patents and numerous pending
patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of experienced industry
leaders and scientists with drug development and global product
launch experience. Tevogen’s leadership believes that accessible
personalized therapeutics are the next frontier of medicine, and
that disruptive business models are required to sustain medical
innovation.
Forward Looking Statements
This press release contains certain forward-looking
statements, including without limitation statements relating to:
expectations regarding the healthcare and biopharmaceutical
industries; Tevogen’s development of, the potential benefits of,
and patient access to its product candidates for the treatment of
infectious diseases, cancer and neurological disorders, including
TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s
ability to develop additional product candidates, including through
use of Tevogen’s ExacTcell platform; the anticipated benefits of
ExacTcell; expectations regarding Tevogen’s future clinical trials;
and Tevogen’s ability to generate revenue in the future.
Forward-looking statements can sometimes be identified by words
such as “may,” “could,” “would,” “expect,” “anticipate,”
“possible,” “potential,” “goal,” “opportunity,” “project,”
“believe,” “future,” and similar words and expressions or their
opposites. These statements are based on management’s expectations,
assumptions, estimates, projections and beliefs as of the date of
this press release and are subject to a number of factors that
involve known and unknown risks, delays, uncertainties and other
factors not under the company’s control that may cause actual
results, performance or achievements of the company to be
materially different from the results, performance or other
expectations expressed or implied by these forward-looking
statements.
Factors that could cause actual results,
performance, or achievements to differ from those expressed or
implied by forward-looking statements include, but are not limited
to: that Tevogen will need to raise additional capital to execute
its business plan, which may not be available on acceptable terms
or at all; the effect of the recent business combination with
Semper Paratus Acquisition Corporation (the “Business Combination”)
on Tevogen’s business relationships, operating results, and
business generally; the outcome of any legal proceedings that may
be instituted against Tevogen related to the Business Combination;
changes in the markets in which Tevogen competes, including with
respect to its competitive landscape, technology evolution, or
regulatory changes; changes in domestic and global general economic
conditions; the risk that Tevogen may not be able to execute its
growth strategies or may experience difficulties in managing its
growth and expanding operations; the risk that Tevogen may not be
able to develop and maintain effective internal controls; costs
related to the Business Combination and the failure to realize
anticipated benefits of the Business Combination; the failure to
achieve Tevogen’s commercialization and development plans, and
identify and realize additional opportunities, which may be
affected by, among other things, competition, the ability of
Tevogen to grow and manage growth economically and hire and retain
key employees; the risk that Tevogen may fail to keep pace with
rapid technological developments to provide new and innovative
products and services or make substantial investments in
unsuccessful new products and services; the ability to develop,
license or acquire new therapeutics; that Tevogen will need to
raise additional capital to execute its business plan, which may
not be available on acceptable terms or at all; the risk of
regulatory lawsuits or proceedings relating to Tevogen’s business;
uncertainties inherent in the execution, cost, and completion of
preclinical studies and clinical trials; risks related to
regulatory review, and approval and commercial development; risks
associated with intellectual property protection; Tevogen’s limited
operating history; and those factors discussed or incorporated by
reference in Tevogen’s Annual Report on Form 10-K and subsequent
filings with the SEC.
You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Tevogen undertakes no obligation to update any
forward-looking statements, except as required by applicable
law.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
過去 株価チャート
から 11 2024 まで 12 2024
Tevogen Bio (NASDAQ:TVGN)
過去 株価チャート
から 12 2023 まで 12 2024